sb 216763 has been researched along with Granulocytic Leukemia, Chronic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Coluccia, AM; De Leo, S; de Luca, E; De Matteis, S; Di Renzo, N; Dini, L; Maffia, M; Palamà, I; Passerini, CG; Reddiconto, G; Toto, C | 1 |
1 other study(ies) available for sb 216763 and Granulocytic Leukemia, Chronic
Article | Year |
---|---|
Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Topics: Antigens, CD34; Apoptosis; Benzamides; beta Catenin; Blotting, Western; Cell Nucleus; Cells, Cultured; Cyclin D1; Cytokines; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maleimides; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Signal Transduction; Thiazoles | 2012 |